Therapeutic Advances in Hematological Malignancies: New Breakthroughs and Future Directions
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 20 July 2026
Special Issue Editor
Special Issue Information
Dear Colleagues,
In the last few years there have been many advances in the field of hematologic malignancies, and many breakthrough treatments are now available. These include CAR T therapy and BITE therapies for lymphoma and multiple myeloma, as well as new targeted drugs in the treatment of leukemia.
These therapeutic advances include better understanding of diagnosis by molecular techniques such as multicolor flow cytometry and advances in molecular genomics with single-cell RNA-Seq and FISH, as well as conventional cytogenetics and DNA sequencing. These diagnostic technologies have opened many possibilities for the diagnosis of new entities, better molecular classification, and new therapeutic avenues to treat complex hematological malignancies.
In addition to better diagnosis, we also have a better understanding of minimal residual disease with treatment goal escalation and de-escalation of treatments according to results of MRT-based assays and technologies. Newer imaging technologies, including MRIs and PET scans, help assess remission status when MRD and imaging are used in conjunction.
With new advances and new breakthroughs, the field is moving so quickly that we need to have a better understanding of the future treatment landscape in the field of hematological malignancies. This Special Issue is going to address the past, present, and future of the therapeutic landscape.
Prof. Dr. Seema Naik
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- leukemia
- lymphoma
- myeloma
- cell therapy
- targeted therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
